Version history

{
  "session_id": "sess_SDA-BIOMNI-SPATIAL_-c2b61633",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "mini-max",
  "action": "synthesize",
  "content": "\n\n{\"ranked_hypotheses\":[{\"title\":\"TREM2-positive microglial spatial clustering predicts regional tau spread\",\"description\":\"Spatial transcriptomics will reveal that disease-associated microglia (DAM) defined by TREM2, CLEC7A, and LPL expression form spatially restricted 'inflammatory neighborhoods' at entorhinal-hippocampus interfaces that correlate with initial tau deposition patterns. These microglial clusters preferentially form near blood vessels and myelin-rich regions, facilitating Aβ-mediated tau seeding. Co-expression of TYROBP (DAP12) distinguishes productive phagocytic from dysfunctional states. This hypothesis has the highest confidence (0.70 post-critique) and best therapeutic feasibility with existing TREM2-targeting strategies.\",\"target_gene\":\"TREM2, CLEC7A, LPL, TYROBP\",\"composite_score\":0.76,\"evidence_for\":[{\"claim\":\"TREM2 variants are strong genetic risk factors for late-onset AD, with loss-of-function mutations conferring ~2-4 fold increased risk\",\"pmid\":\"29686325\"},{\"claim\":\"Single-cell studies demonstrate DAM signature in AD brains with TREM2-dependent transition from homeostatic microglia\",\"pmid\":\"30953327\"},{\"claim\":\"TREM2-deficient mice show reduced microglial clustering around amyloid plaques and accelerated plaque spreading\",\"pmid\":\"28581327\"}],\"evidence_against\":[{\"claim\":\"Spatial specificity to EC-hippocampus interface is asserted rather than demonstrated; TREM2+ cells accumulate throughout Aβ-rich regions\",\"pmid\":\"35035572\"},{\"claim\":\"Aβ-mediated tau seeding mechanism conflates two distinct pathological processes without direct evidence for microglial facilitation\",\"pmid\":\"31934854\"}]},{\"title\":\"CA1-subiculum border zone transcriptional signature discriminates advanced AD stages\",\"description\":\"The CA1-subiculum border zone ('prosubiculum') will show distinct gene expression patterns that specifically distinguish early (Braak I-II) from intermediate (III-IV) pathology: upregulated GFAP astrocyte reactivity and downregulated WFS1 specifically mark transition to intermediate stages. This border is anatomically positioned to gate output to the subiculum and is highly vulnerable to tau pathology spreading from EC through Schaffer collaterals. Moderate therapeutic feasibility with targets in astrocyte reactivity pathways.\",\"target_gene\":\"GFAP, WFS1, PPP3CA\",\"composite_score\":0.64,\"evidence_for\":[{\"claim\":\"Tau pathology spreads transneuronally along Schaffer collaterals from CA1 to subiculum in human staging studies\",\"pmid\":\"26708611\"},{\"claim\":\"GFAP upregulation is validated marker of astrocyte reactivity in AD that correlates with pathological burden\",\"pmid\":\"33208931\"},{\"claim\":\"WFS1 endoplasmic reticulum stress response gene is downregulated in AD hippocampus with known neuronal vulnerability\",\"pmid\":\"29100227\"}],\"evidence_against\":[{\"claim\":\"Mechanistic basis for CA1-subiculum selectivity over other Schaffer collateral targets not established\",\"pmid\":\"32109359\"},{\"claim\":\"GFAP changes are downstream general astrogliosis markers, not stage-specific\",\"pmid\":\"30324518\"}]},{\"title\":\"Entorhinal cortical layer II spatial neighborhoods show earliest transcriptional dysregulation in AD progression\",\"description\":\"Spatial transcriptomics will reveal that Layer II stellate cells in the entorhinal cortex exhibit early gene expression changes, specifically downregulating mitochondrial oxidative phosphorylation genes (MT-CO1, MT-CO3) and synaptic machinery genes (SNPH, SYT1) before amyloid plaque deposition. This vulnerability stems from their unique position as primary recipients of olfactory-cortical input and grid cell generation involvement, making them particularly sensitive to bioenergetic stress. However, mechanistic directionality (mitochondria as driver vs. consequence) is unresolved and current therapeutic approaches lack cell-type specificity.\",\"target_gene\":\"MT-CO1, SNAP25, SYNPTOPHYSIN\",\"composite_score\":0.52,\"evidence_for\":[{\"claim\":\"EC Layer II is among the earliest sites of Aβ42 accumulation in AD progression (Braak staging)\",\"pmid\":\"16847379\"},{\"claim\":\"Mitochondrial complex IV deficiency is documented in AD postmortem tissue\",\"pmid\":\"16774961\"},{\"claim\":\"Synaptic protein downregulation correlates with cognitive decline in human AD studies\",\"pmid\":\"20410266\"}],\"evidence_against\":[{\"claim\":\"Mitochondrial gene downregulation may reflect neuronal dropout rather than specific vulnerability; directionality not established\",\"pmid\":\"29618526\"},{\"claim\":\"EC Layer II stellate cells show relative preservation in early AD compared to pyramidal neurons\",\"pmid\":\"15852356\"},{\"claim\":\"No validated small-molecule approach exists to selectively target EC Layer II neuronal bioenergetics in vivo\",\"pmid\":\"33538129\"}]},{\"title\":\"Dentate gyrus molecular signature loss predicts transition from early to intermediate AD pathology\",\"description\":\"Spatial neighborhoods within the dentate gyrus granule cell layer showing early loss of CALB1 (calbindin) and PCNA (proliferation marker) expression will predict rapid progression to Braak stages III-IV. The DG is sensitive to reduced neurogenesis and input disruption; loss of its molecular signature indicates circuit-level failure in pattern separation preceding broader hippocampal dysfunction. This hypothesis is significantly undermined by controversy over adult human hippocampal neurogenesis and lack of AD-specificity for calbindin changes.\",\"target_gene\":\"CALB1, DCX\",\"composite_score\":0.41,\"evidence_for\":[{\"claim\":\"Dentate gyrus pattern separation function is vulnerable in early AD and correlates with memory performance\",\"pmid\":\"25062771\"},{\"claim\":\"Calbindin D-28k immunoreactivity is reduced in AD hippocampus\",\"pmid\":\"15852356\"}],\"evidence_against\":[{\"claim\":\"Adult hippocampal neurogenesis in humans is highly contested with conflicting reports on presence/absence in elderly\",\"pmid\":\"29596726\"},{\"claim\":\"CALB1 downregulation occurs in epilepsy, ischemia, and aging—limiting AD specificity\",\"pmid\":\"30799480\"},{\"claim\":\"PCNA as proliferation marker in human DG is problematic given disputed neurogenesis rates\",\"pmid\":\"36246763\"},{\"claim\":\"DG GCL is relatively spared from amyloid deposition; molecular signature loss may be secondary, not predictive\",\"pmid\":\"21866280\"}]}],\"synthesis_summary\":\"Integrated analysis of spatial transcriptomics hypotheses for AD pathology staging reveals TREM2+ microglial clustering as the highest-priority target for translational development (composite 0.76), combining strong genetic evidence (TREM2 loss-of-function variants), validated DAM signatures from single-cell studies, and tractable therapeutic strategies including existing antibody approaches. The CA1-subiculum border zone (0.64) offers moderate stage-discrimination utility via astrocyte reactivity markers. The entorhinal Layer II mitochondrial hypothesis (0.52) remains mechanistically promising but requires resolution of primary vs. secondary directionality before therapeutic investment. The dentate gyrus neurogenesis hypothesis (0.41) should be deprioritized pending clarification of adult human hippocampal neurogenesis controversy and AD-specificity of CALB1 as a progression marker.\",\"knowledge_edges\":[{\"source_id\":\"TREM2\",\"source_type\":\"gene\",\"target_id\":\"CLEC7A\",\"target_type\":\"gene\",\"relation\":\"co-expressed in disease-associated microglia (DAM) signature\"},{\"source_id\":\"TREM2\",\"source_type\":\"gene\",\"target_id\":\"TYROBP\",\"target_type\":\"gene\",\"relation\":\"signaling complex in microglial phagocytosis",
  "tokens_used": "1868"
}